66 results
F-3
BLRX
Bioline Rx Ltd
26 Dec 18
Shelf registration (foreign)
4:11pm
to ordinary shares that may be acquired upon exercise of outstanding warrants issued to Kreos Capital V (Expert Fund) L.P.
Estimated solely … Depositary Shares Representing 957,549 Ordinary Shares
This prospectus relates to the resale by Kreos Capital V (Expert Fund) L.P., or the Selling
6-K
EX-99
BLRX
Bioline Rx Ltd
26 Feb 21
Extraordinary General Meeting of Shareholders on
4:30pm
expert), our Compensation Committee and Board of Directors have determined that it is in the best interests of the Company to also provide differential … In exceptional circumstances (e.g., a key opinion leader or globally recognized expert), higher compensation may be paid to a director candidate in accordance
6-K
EX-10.4
BLRX
Bioline Rx Ltd
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
: October 2, 2018 (“Issuance Date”)
This certifies that, for value received, KREOS CAPITAL V (EXPERT FUND) L.P. or its permitted assigns (the “Holder … : 03-6087734
Attn: Simon Weintraub, Adv.
E-mail: simonw@arnon.co.il
If to the Holder:
Kreos Capital V (Expert Fund) L.P.
47 Esplanade, St Helier
6-K
EX-5.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
” and “Enforceability of Civil Liabilities” in the Prospectus Supplement. In giving this consent, we do not thereby admit that we are an “expert” within the meaning
6-K
uk9vll
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
6-K
EX-1
b36dbrsin7pejs5c3
6 Sep 11
Orally-Available Molecule for the Treatment of
12:00am
F-3
EX-5.1
56jyvyk
26 Dec 18
Shelf registration (foreign)
4:11pm
6-K
EX-99
hex90ulusgmin w2s
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
F-1
EX-10.16
sq6za q3i
24 Sep 10
Registration statement (foreign)
12:00am
20FR12B
EX-4.16
klnmfwagubjjqqdl8uh
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
20-F/A
EX-4.33
aarbe55
31 May 16
Annual report (foreign) (amended)
12:00am
20-F/A
xi5n5i zer
30 Jul 19
Annual report (foreign) (amended)
7:00am
6-K
EX-99
cpgbykkldr4 l7cgjs
8 Nov 18
BioLineRx Reports Significant Progress Across Oncology
7:00am
20-F/A
1tphiz 2yh8fpru6t
5 Jun 19
Annual report (foreign) (amended)
7:00am
6-K
EX-10.3
vnhukb
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
6-K
EX-99
44icxltjrmiu8j22
30 Apr 13
Current report (foreign)
12:00am
6-K
EX-99.1
19ry4x8
3 Mar 14
Current report (foreign)
12:00am
6-K
EX-1
r8f2q4fkhilrexmaj
28 May 19
Current report (foreign)
7:04am